Colombia Surrogacy IVF Add-Ons: Why More Treatment Does Not Always Mean Better Results
New research published in Human Reproduction explores why fertility patients consider expensive IVF add-ons—and why CanBaby Surrogacy believes medical evidence should come before additional costs.
Published November 3, 2026
When an IVF cycle fails, intended parents naturally want to understand what went wrong. After a second or third unsuccessful attempt, the questions often become more urgent.
Should we try a different embryo transfer protocol? Would an additional test help? Could an expensive treatment improve our chances of finally having a baby?
These are reasonable questions. Unfortunately, not every treatment marketed as an IVF improvement has reliable evidence that it increases the chance of a live birth.
For intended parents considering Colombia surrogacy IVF add-ons, this distinction matters.
On October 29, 2026, the medical journal Human Reproduction published a study examining why patients consider additional IVF treatments even when their benefits remain uncertain.
The findings raise an important issue for fertility patients worldwide: when hope becomes stronger after repeated disappointment, how can families distinguish meaningful medical care from unnecessary treatment?
At CanBaby Surrogacy, our position is clear.
We do not recommend IVF add-ons simply because patients are willing to pay for them. If an additional treatment lacks credible medical evidence and a sound clinical reason, we will not promote it as a way to improve success rates.
New IVF Research Published in Human Reproduction on October 29, 2026
The study, titled Attitude and acceptability of IVF add-ons to improve reproductive outcomes: a focus group qualitative study, was published by Kimmee Khan and colleagues in Human Reproduction.
Researchers conducted three online focus groups involving 12 women living in the United Kingdom. All participants had previously undergone assisted reproductive treatment, and most had experience with IVF add-ons.
The researchers wanted to understand how patients evaluate the effectiveness, safety, cost, and acceptability of additional fertility treatments.
Their findings revealed something important.
Although participants generally considered a live birth the most meaningful outcome, many also valued intermediate milestones, including egg retrieval, embryo development, and a positive pregnancy test.
These milestones provided a sense of progress during an uncertain treatment journey.
The study also found that some participants became more open to treatments supported by weaker evidence after experiencing repeated unsuccessful IVF cycles.
Cost remained important, but the possibility of improving treatment outcomes often carried greater emotional weight.
The research did not test whether any IVF add-on improved pregnancy or live birth rates. It explored patient attitudes and decision-making.
Its findings also have limitations. With only 12 participants, all women from the United Kingdom, the study cannot represent every fertility patient or intended parent.
Nevertheless, it offers valuable insight into the emotional and financial decisions surrounding fertility treatment.
Why IVF Patients Consider Add-Ons After Repeated Failures
When Doing Something Feels Better Than Doing Nothing
For many intended parents, an unsuccessful IVF cycle involves more than financial loss.
It may mean another month of waiting, additional medical appointments, and renewed uncertainty about whether parenthood will ever become possible.
After repeated failures, patients may feel that repeating the same treatment without making changes is unacceptable.
An additional test or procedure can create a sense of action and control.
This helps explain why some patients consider treatments even when scientific evidence remains uncertain.
The new Human Reproduction study identified this tension between patients’ desire for effective treatment and their fear of missing an opportunity that might help.
However, a treatment that creates hope does not necessarily improve reproductive outcomes.
A Positive Pregnancy Test Is Not the Same as a Live Birth
Fertility treatment involves several important milestones.
An IVF laboratory may retrieve eggs, achieve fertilization, and develop embryos suitable for transfer.
A pregnancy test may then become positive.
Each step matters, but none guarantees that a baby will ultimately be born.
This distinction is particularly important when evaluating IVF add-ons.
A treatment might appear promising because it changes a laboratory measurement or another intermediate outcome.
Yet that improvement does not automatically demonstrate an increased live birth rate.
For intended parents, the most meaningful question remains whether the additional intervention improves the chance of having a healthy baby.
What Are IVF Add-Ons in Colombia Surrogacy?
IVF add-ons are additional tests, procedures, or treatments offered alongside established fertility care.
Some aim to improve embryo implantation. Others claim to enhance embryo selection, support the immune system, or identify a more favorable time for embryo transfer.
These interventions vary considerably in their scientific evidence, safety profiles, and potential clinical value.
An add-on is not automatically ineffective simply because it is additional to standard treatment. Some interventions may have appropriate uses in selected circumstances.
The problem arises when providers routinely recommend expensive procedures without reliable evidence of benefit for the individual patient.
The European Society of Human Reproduction and Embryology (ESHRE) published good practice recommendations on IVF add-ons, emphasizing the importance of evaluating effectiveness, safety, and clinical relevance.
For international intended parents pursuing surrogacy in Colombia, these principles should apply just as they would in Canada, the United States, or Europe.
The location of treatment should not lower the standard of medical evidence.
ERA Testing: Does It Improve Embryo Transfer Success?
Endometrial Receptivity Analysis, often called ERA, is one of the better-known IVF add-ons.
It examines gene expression in an endometrial biopsy to estimate the timing of the implantation window.
The underlying idea is that identifying a personalized transfer window might improve the chance of implantation.
However, a plausible biological explanation is not the same as proof of clinical benefit.
The UK’s Human Fertilisation and Embryology Authority (HFEA) has reviewed evidence on endometrial receptivity testing and does not support its routine use to improve live birth outcomes.
ESHRE also does not recommend currently available endometrial receptivity tests for routine clinical use.
This does not mean every patient with repeated implantation failure should receive exactly the same evaluation.
It means clinicians should distinguish between investigations supported by an individual medical indication and tests marketed as universal solutions.
At CanBaby, we would not recommend routine ERA testing simply because an intended parent or surrogate experienced an unsuccessful embryo transfer.
Any proposal for additional testing should begin with a review of the clinical circumstances and the available evidence.
Immune Treatments: More Intervention Can Mean More Risk
Some fertility clinics offer immune-related tests or treatments to patients who have experienced implantation failure or miscarriage.
Examples include intravenous immunoglobulin (IVIG), intralipid infusions, corticosteroids, and certain immune-cell investigations.
These approaches are sometimes promoted on the theory that immune-system activity may interfere with implantation.
However, the relationship between reproductive immunology and successful pregnancy is complex.
The ESHRE recommendations do not support routine use of several immune tests and treatments as IVF add-ons. The evidence for improving live birth outcomes remains insufficient or unfavorable, and some treatments carry safety concerns.
The HFEA guidance on immunological treatments also distinguishes experimental fertility add-ons from medically necessary treatment for a diagnosed immune condition.
This distinction is essential.
A patient with a confirmed medical condition may need treatment prescribed by an appropriate specialist. That is different from giving immune medications to otherwise healthy fertility patients without a demonstrated indication.
CanBaby does not support adding immune treatments to an IVF plan simply to create the impression that more is being done.
After a Failed Embryo Transfer, What Should Be Evaluated First?
Before discussing expensive add-ons, the treating medical team should review the available evidence from the previous cycle.
The evaluation may include embryo development, embryo quality, laboratory records, endometrial preparation, medication timing, transfer conditions, and relevant reproductive or medical history.
Not every failed transfer indicates an underlying abnormality.
Even when the laboratory produces a suitable embryo and the surrogate receives appropriate preparation, implantation may not occur.
An unsuccessful attempt therefore does not automatically justify extensive additional testing.
For some patients, the most appropriate next step may be another carefully planned embryo transfer.
For others, the medical history may reveal a specific reason to investigate further.
The important principle is to identify a clinical question before ordering a test.
CanBaby discusses this process in our related article, Failed Embryo Transfer in Colombia Surrogacy: What Happens Next?.
A failed embryo transfer deserves a medical review, not an automatic shopping list of additional procedures.
CanBaby’s Approach: IVF Expertise Before Additional Treatment Costs
CanBaby Surrogacy was founded with professional IVF and embryology experience.
Our background is not limited to finding gestational surrogates or coordinating international appointments.
We understand embryo development, laboratory procedures, fertilization, and the factors that can influence treatment outcomes.
This experience shapes how we discuss unsuccessful cycles with intended parents.
When a treatment does not work, we do not assume that the solution must be another expensive test.
Instead, we consider what the existing medical information can tell us and whether additional investigations have a reasonable clinical purpose.
Our goal is to help clients make informed decisions rather than encourage spending driven by anxiety.
This approach also guides our medical screening before accepting clients into our Colombia Egg Donation, IVF and Surrogacy Program.
We believe patients should understand why a test or treatment is recommended, what evidence supports it, and whether its results would meaningfully change the treatment plan.
Why CanBaby Does Not Recommend Unproven IVF Add-Ons Simply to Increase Costs
Our position is straightforward: we do not recommend optional IVF procedures that lack credible evidence of benefit and a medically justified reason for use.
We do not believe intended parents should pay for additional interventions merely because they have experienced disappointment or because a treatment sounds technologically advanced.
Before supporting an additional procedure, we consider whether it addresses a genuine clinical concern.
We also examine whether reliable studies demonstrate improved outcomes, especially live birth rates.
Safety matters just as much as effectiveness.
An intervention that offers no proven benefit may still involve medication side effects, invasive procedures, delays, or financial costs.
We also recognize that scientific evidence evolves.
A procedure that lacks adequate evidence today may become useful in the future if well-designed research demonstrates clear benefits.
Until then, patients deserve an accurate explanation of the uncertainty.
This is not opposition to innovation. It is a commitment to responsible reproductive medicine.
How This Philosophy Applies to Our $75,000 Guaranteed Birth Program
CanBaby’s $75,000 Guaranteed Birth Program combines donor eggs, IVF, and gestational surrogacy for medically eligible intended parents.
The program includes covered embryo transfers until one live birth, subject to the signed agreement and applicable medical eligibility requirements.
Because multiple transfers may be necessary, our team must carefully evaluate medical risks and treatment decisions.
We do not believe that a Guaranteed Birth program should become an excuse to introduce unnecessary medical procedures.
Repeated treatment attempts can already create substantial emotional and physical demands for the people involved.
When an embryo transfer fails, our responsibility is to work with the treating clinic to determine the next medically appropriate step.
That might involve reviewing the treatment protocol, evaluating relevant clinical findings, or proceeding with another transfer.
It should not automatically involve charging for an unproven add-on.
You can read more about the medical philosophy behind our program in Why CanBaby Offers a Guaranteed Birth Program.
Our contractual coverage does not eliminate the biological uncertainty of IVF. It provides a defined treatment framework for eligible clients.
The same evidence-based principles apply whether an intended parent uses our Guaranteed Birth package or our Existing Embryo Surrogacy Program.
Questions Intended Parents Should Ask Before Paying for an IVF Add-On
Before agreeing to an additional fertility treatment, intended parents should feel comfortable asking their clinic several questions.
What specific medical problem is this intervention intended to address?
Is there reliable evidence that it improves live birth rates for patients with similar circumstances?
What are the risks, costs, and possible treatment delays?
Would the results of the test change the medical plan?
And what would happen if the patient chose not to undergo the procedure?
These questions are especially important for international patients who may receive treatment recommendations from several different professionals.
A responsible fertility provider should be willing to discuss uncertainty openly.
Patients should not feel pressured to purchase an additional procedure simply because they fear regretting the decision later.
Frequently Asked Questions About Colombia Surrogacy IVF Add-Ons
Are IVF add-ons necessary for surrogacy in Colombia?
No. IVF add-ons are not automatically required for gestational surrogacy in Colombia. Their use should depend on medical indications and evidence of clinical benefit.
Should I request ERA testing after one failed embryo transfer?
One unsuccessful transfer does not automatically justify ERA testing. Current professional guidance does not recommend routine endometrial receptivity testing to improve IVF outcomes.
Can immune treatments improve implantation?
Evidence does not support routinely prescribing several immune-related treatments as IVF add-ons. Some also carry potential risks. Treatment for a diagnosed immune disorder is a separate medical issue.
Does CanBaby recommend additional tests after repeated IVF failures?
We support medically justified investigations when the treating specialists identify a relevant clinical concern. We do not recommend tests solely because a patient has experienced repeated failures or is willing to pay for additional treatment.
Can IVF add-ons guarantee a live birth?
No. No IVF add-on can guarantee a live birth. Patients should be cautious about claims that an optional procedure will eliminate the risk of treatment failure.
The Best Fertility Care Is Not Always the Most Expensive
The October 2026 Human Reproduction study highlights a difficult reality of fertility treatment.
Patients may become more willing to consider uncertain interventions as unsuccessful attempts accumulate.
Their decisions often reflect a combination of hope, financial concerns, previous experiences, and the desire to avoid future regret.
Fertility professionals should recognize these emotions without using them to justify unnecessary treatment.
At CanBaby Surrogacy, we believe the goal is not to perform the greatest number of procedures.
It is to recommend appropriate medical care, explain uncertainty, and help intended parents make informed decisions based on the best available evidence.
More IVF treatment does not always mean better IVF treatment.
For families pursuing surrogacy in Colombia, medical transparency and responsible treatment planning matter more than an impressive list of expensive add-ons.
Discuss Your IVF and Surrogacy Options With CanBaby
If you have experienced unsuccessful IVF cycles or embryo transfers, our team can help you understand your available options and the medical questions worth discussing with your treating specialists.
We provide international surrogacy consulting supported by professional embryology experience.
Whether you already have frozen embryos or are considering donor eggs and gestational surrogacy, we believe every treatment recommendation should have a clear purpose.
Schedule a Private Consultation With CanBaby Surrogacy
Scientific References
Khan K, Nicholson L, Osinibi M, et al. Attitude and acceptability of IVF add-ons to improve reproductive outcomes: a focus group qualitative study. Human Reproduction. Published October 29, 2026. https://doi.org/10.1093/humrep/deag164
ESHRE Add-ons Working Group. Good practice recommendations on add-ons in reproductive medicine. Human Reproduction. 2023;38(11):2062–2104. https://doi.org/10.1093/humrep/dead184
Human Fertilisation and Embryology Authority. Treatment add-ons with limited evidence. https://www.hfea.gov.uk/treatments/treatment-add-ons/
Human Fertilisation and Embryology Authority. Endometrial receptivity testing. https://www.hfea.gov.uk/treatments/treatment-add-ons/endometrial-receptivity-testing/
Human Fertilisation and Embryology Authority. Immunological tests and treatments for fertility. https://www.hfea.gov.uk/treatments/treatment-add-ons/immunological-tests-and-treatments-for-fertility/